



WORLD CANCER ACTIONS

May 08 & 09, 2019

Venue

Barceló Valencia Hotel - València - Spain

07:45-08:45 | Registrations

08:45-09:00 | Inaugural Ceremony

Keynote Presentation

@ Celeste 1

09:00-09:30

Sinonasal Histocytosis with Massive Lymphadenopathy (Rosai-Dorfman Disease) Mimicking Malignant Sarcoma

Beverly Y Wang, University of California Irvine Health, USA

09:30-15:55

Speaker Presentations

@ Celeste 1

Sessions Chair

Beverly Y. Wang, University of California Irvine Health, USA

Mildred Acevedo Duncan, University of South Florida, USA

09:30-11:35

Organ Specific Cancer: Basic and Clinical Studies

09:30-09:55

Preclinical Testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide (ICA-1); A Potent Protein Kinase C- α inhibitor as a Potential Anticancer Drug

Mildred Acevedo-Duncan, University of South Florida, USA

09:55-10:20

Photochemical Internalization - Bladder Cancer

Odrun Gederaas, Norwegian University of Science and Technology (NTNU), Norway

10:20-10:45

Coffee Break

@ Foyer Area

10:45-11:10

Natural Killer Cells and Neuroblastoma: Molecular Interactions and Escape Mechanisms

Roberta Castriconi, University of Genoa, Italy

11:10-11:35

RhoB in Radioresistance of Colorectal Cancer

Xiao-Feng Sun, Linkoping University, Sweden

11:35-15:55

Immuno Oncology

Promising Innovations and Drugs

Cancer Therapeutics and Therapies

11:35-12:00

Suicide Genes for Cancer Therapy

Houria Boulaiz Tassi, University of Granada, Spain

12:00-12:25	<p>The Brain-penetrant Clinical ATM inhibitor AZD1390 Radiosensitizes and Improves Survival of Preclinical Brain Tumor Models</p> <p>Steve T Durant, AstraZeneca, UK</p>	
12:25-12:50	<p>Tumor-associated NADH Oxidase (tNOX)-NAD⁺-sirtuin 1 (SIRT1) Axis Fine-tuned by ROS and p53 Contributes to Cellular Responses Against Oxaliplatin in Human Cancer Cells</p> <p>Pin Ju Chueh, National Chung Hsing University, Taiwan</p>	
12:50-13:15	<p>Proton Beam Therapy for Craniopharyngioma: Experiences from a Prospective Data Base</p> <p>Peters Sarah, West German Cancer Center (WTZ), Germany</p>	
13:15-14:15	Lunch	@ Foyer Area
14:15-14:40	<p>SURF6 is a Positive Regulator of Proliferation</p> <p>Anastasiia Moraleva, Institute of Bioorganic Chemistry, Russia</p>	
14:40-15:05	<p>Designed Cisplatin and Metformin Nano-Cubosomes Increases Drug Cytotoxicity Against CRC</p> <p>Mona Magdy Saber, Cairo University, Egypt</p>	
15:05-15:30	<p>Adipocytes Modulate Invasive Phenotype of Cancer Cells</p> <p>Berthabetty Schwartz, The Hebrew University of Jerusalem, Israel</p>	
15:30-15:55	<p>Calixpyrroles as New Potential Anti-Cancer Drugs</p> <p>Franz H. Kohnke, University of Messina, Italy</p>	
15:55-16:20	Coffee Break	@ Foyer Area

Keynote Presentation

@ Celeste 1

09:00-09:30

Androgen receptor signaling in urothelial tumorigenesis: Androgen deprivation as a promising chemopreventive option for bladder tumor recurrence

Hiroshi Miyamoto, University of Rochester Medical Center, USA

09:30-15:55

Featured Presentations

@ Celeste 1

Sessions Chair

Hiroshi Miyamoto, University of Rochester Medical Center, USA

09:30-15:55

Diagnosis of Different Types of Cancer: Imaging and Studies
Cancer Prevention and Management
Case Studies
Cancer Genetics and Epigenetics

09:30-09:55

Respiratory Microbiota in Lung-cancer Patients

Urszula - Kosikowska, Medical University of Lublin, Poland

09:55-10:20

Sonic Hedgehog Role on Glioblastoma Behavior

Tania Spohr, Paulo Niemeyer State Brain Institute, Brazil

10:20-10:45

18F Fludarabine for Lymphoproliferative Diseases

Louisa Malika Barre, Cyceron, France

10:45-11:10

Coffee Break

@ Foyer Area

11:10-11:35

MASS in Metastatic Spine Disease

Eric M Massicotte, University of Toronto, Canada

11:35-12:00

TRAP1 Regulation of Energy Metabolism in Cancer

Franca Esposito, University of Naples Federico II, Italy

12:00-12:25

Perioperative Management for Cancer Patients

Changhong Miao, Fudan University Shanghai Cancer Center, China

12:25-12:50

Gastric Cancer: Quality of Life and Palliative Care

Chandana Banerjee, City of Hope National Medical Center, USA

12:50-13:15

Histone Deacetylase Inhibition Restores Expression of Hypoxia-inducible Protein NDRG1 in Pancreatic Cancer

Celine Tiffon, National Cancer Institute, France

13:15-14:15

Lunch

@ Foyer Area

14:15-14:40	Aspects and Peculiarities of Boron Neutron Capture Therapy (BNCT) Grazia Gambarini, University of Milan, Italy
14:40-15:05	[^{99m} Tc]DGA1, a Novel Radiotracer Based on a CCK2R-Antagonist for Diagnostic Imaging of Human Cancer: First Comparisons with [^{99m} Tc]DG2 Thea Maina-Nock, Director of Research Molecular Radiopharmacy, Greece
15:05-15:30	End of Life Option Act: Where are We Today ? Sorin - Buga, City of Hope National Medical Center, USA
15:30-15:55	Clinical Trials and Real Life- Safety and Survival Daniella Bajzath, PSI CRO AG, Switzerland
15:55-16:20	Coffee Break @ Foyer Area

Poster Presentations

16:20-17:20 @ Celeste 1

Poster-1	The Role of STAT3 and its Phosphorylation Puzzle in Clear Cell Renal Cell Carcinoma (ccRCC) Jazmine Arevalo Bautista, VHIR Vall d'Hebron Research Institute, Spain
Poster-2	The Mortality Analysis in Hepatocellular Carcinoma in Kaohsiung Medical University Hospital Shinn Cherng Chen, Kaohsiung Medical University, Taiwan
Poster-3	Family History of Cancer and the Risk of Childhood Solid Tumours: A Norwegian Nationwide Register-Based Cohort Study Ruby Del Risco Kollerud, University of Oslo, Norway
Poster-4	Identification of Topics Explained by Home Doctors to Family Caregivers with Cancer Patients Died at Home: A Quantitative Text Analysis of Actual Speech in all Visits Hiroki Chiba, Medical Education Kitasato University School of Medicine, Japan
Poster-5	The lncRNA ENST00000419368 Exerts Anticancer Effect in Ovarian Cancer by Down-Regulating IFN-STAT1 Signaling Pathway Juan Xu, Nanjing Maternity and Child Health Care Hospital, China
Poster-6	Synergetic Antitumor Effect of Gef Gene and New 1,4-benzoxazepin-2,6-dichloropurine Derivatives as New Strategy for Cancer Therapy Yaiza Jimenez Martinez, University of Granada, Spain
Poster-7	Structural Intervention vs. Protease-Inhibition Methods to Improve NTS1R-Tumor Uptake of Neurotensin Radiotracers: A Preclinical Comparison of ^{99m} Tc-DT1 and ^{99m} Tc-DT Thea Maina-Nock, Director of Research Molecular Radiopharmacy, Greece

NOTES

We wish to meet you again at **WCA-2020**

Organising Secretariat

Research Fringe

94 St. Albans Road, Watford,
Hertfordshire WD17 1SJ, United Kingdom

Contact: +44-(0)-208-638-5556

E-mail: admin@researchfringe.com

